NEW YORK (GenomeWeb News) – Building on an existing relationship, Agilent Technologies and Chungnam National University in South Korea today announced new initiatives in the area of glycomics.
The new research will aim to develop new biomarkers and new therapeutic antibodies against diseases such as cancer, they said.
Agilent and the university's Graduate School of Analytical Science and Technology (GRAST) will create the Asia Glycomics Education Center to support collaborative university and industry education and cross-training. The Seoul, South Korea-based university will develop and conduct training programs in different methods of glycan analysis. The progams will be free to scientists and researchers endorsed by Agilent in South Korea and the South Asia-Pacific region.
In the new center, Agilent will install a 6540 quadrupole time-of-flight with Chip/2D nanoHPLC system, which will be used to develop new applications or analytical methods in glycomics and glycoproteomics, the partners said.
They added that Hyun-Joo An, a professor at GRAST, and Rudolf Grimm, Agilent's director of science and technology and manager of collaborations in the Asia-Pacific area, will continue working together on the new initiatives.
“In science, discovery is a long and arduous road dependent on the best people, process and technology,” Rod Minett, general manager of Agilent’s Life Sciences Group in South Korea and the South Asia-Pacific region, said in a statement. “For this collaboration with Chungnam National University, we are going into the next phase of our journey to develop and enhance the biosimilars industry, which will help scientists develop new treatments to cure or prevent diseases.”